Evaluating clinical utility of ctDNA monitoring for recurrence prediction in resected extrahepatic cholangiocarcinoma.
作者信息
Zhang Ying, Wang Kui, Song Zhengji
机构信息
Department of Gastroenterology, The First People's Hospital of Yunnan Province, The Affiliated Hospital of Kunming University of Science and Technology, Kunming, Yunnan, China.
Department of Gastroenterology, Qilu Hospital of Shandong University, Jinan, Shandong, China.
出版信息
J Hepatol. 2025 Jun;82(6):e317. doi: 10.1016/j.jhep.2024.11.040. Epub 2024 Dec 9.
PMID:39662704
Abstract
摘要
相似文献
1
Evaluating clinical utility of ctDNA monitoring for recurrence prediction in resected extrahepatic cholangiocarcinoma.评估ctDNA监测在预测肝外胆管癌切除术后复发中的临床应用价值。
J Hepatol. 2025 Jun;82(6):e317. doi: 10.1016/j.jhep.2024.11.040. Epub 2024 Dec 9.
2
Reply to: "Evaluating clinical utility of ctDNA monitoring for recurrence prediction in resected extrahepatic cholangiocarcinoma".回复：“评估ctDNA监测在肝外胆管癌切除术后复发预测中的临床应用价值”
J Hepatol. 2025 Jun;82(6):e318-e319. doi: 10.1016/j.jhep.2025.02.005. Epub 2025 Feb 12.
3
Circulating tumor DNA status and dynamics predict recurrence in patients with resected extrahepatic cholangiocarcinoma.循环肿瘤DNA状态及动态变化可预测肝外胆管癌切除术后患者的复发情况。
J Hepatol. 2025 May;82(5):861-870. doi: 10.1016/j.jhep.2024.10.043. Epub 2024 Nov 10.
4
Circulating tumor DNA analysis guiding adjuvant treatment in resected stage III cholangiocarcinoma: a case report.循环肿瘤DNA分析指导Ⅲ期胆管癌切除术后辅助治疗：一例报告
J Gastrointest Oncol. 2024 Feb 29;15(1):485-490. doi: 10.21037/jgo-23-815. Epub 2024 Jan 16.
5
Dynamic recurrence risk and adjuvant chemotherapy benefit prediction by ctDNA in resected NSCLC.ctDNA 动态复发风险和辅助化疗获益预测在可切除 NSCLC 中的应用。
Nat Commun. 2021 Nov 19;12(1):6770. doi: 10.1038/s41467-021-27022-z.
6
Nerve Growth Factor Expression Is Not Associated with Perineural Invasion in Extrahepatic Cholangiocarcinoma.神经生长因子表达与肝外胆管癌的神经周围侵犯无关。
Dig Dis Sci. 2016 Mar;61(3):774-84. doi: 10.1007/s10620-015-3953-9. Epub 2015 Nov 7.
7
Tumor-informed or tumor-agnostic circulating tumor DNA as a biomarker for risk of recurrence in resected colorectal cancer patients.肿瘤特异性或肿瘤非特异性循环肿瘤DNA作为切除术后结直肠癌患者复发风险的生物标志物。
Front Oncol. 2023 Jan 26;12:1055968. doi: 10.3389/fonc.2022.1055968. eCollection 2022.
8
Circulating Tumor DNA Profiling in Liver Transplant for Hepatocellular Carcinoma, Cholangiocarcinoma, and Colorectal Liver Metastases: A Programmatic Proof of Concept.肝细胞癌、胆管癌和结直肠癌肝转移患者肝移植中的循环肿瘤DNA分析：一项方案性概念验证研究
Cancers (Basel). 2024 Feb 25;16(5):927. doi: 10.3390/cancers16050927.
9
Longitudinal Monitoring of Circulating Tumor DNA From Plasma in Patients With Curative Resected Stages I to IIIA EGFR-Mutant Non-Small Cell Lung Cancer.根治性切除术后Ⅰ期到ⅢA 期 EGFR 突变非小细胞肺癌患者血浆中循环肿瘤 DNA 的纵向监测。
J Thorac Oncol. 2023 Sep;18(9):1199-1208. doi: 10.1016/j.jtho.2023.05.027. Epub 2023 Jun 10.
10
Recurrence and prognostic factors of ampullary carcinoma after radical resection: comparison with distal extrahepatic cholangiocarcinoma.壶腹癌根治性切除术后的复发及预后因素：与肝外胆管远端癌的比较
Ann Surg Oncol. 2007 Nov;14(11):3195-201. doi: 10.1245/s10434-007-9537-y. Epub 2007 Aug 19.
引用本文的文献
1
Bibliometric analysis of pancreatic cancer liver metastasis research: global trends, collaborations, and emerging research hotspots.胰腺癌肝转移研究的文献计量分析：全球趋势、合作及新兴研究热点
Front Oncol. 2025 Jul 15;15:1546400. doi: 10.3389/fonc.2025.1546400. eCollection 2025.
Zotero 插件